Polycystic kidney disease: Tolvaptan slows disease progression in late-stage ADPKD

Polycystic kidney disease: Tolvaptan slows disease progression in late-stage ADPKDPolycystic kidney disease: Tolvaptan slows disease progression in late-stage ADPKD, Published online: 02 January 2018; doi:10.1038/nrneph.2017.180New data from the REPRISE trial confirms that tolvaptan slows the progression of autosomal dominant polycystic disease (ADPKD). Although not yet approved by the United States Food and Drug administration, tolvaptan is now likely to become standard care for early and later stages of ADPKD in Europe and in various countries worldwide.

Source: Nature Reviews Nephrology - January 2, 2018 Category: Urology & Nephrology Authors: Albert C. M. Ong Source Type: research